CCL is pleased to announce the acquisition of a majority stake in Dermogyn s.r.l., Italy. Dermogyn is an upcoming research-based consumer healthcare company with an innovative portfolio of patented dermatology and intimate health & hygiene products. This strategic move represents a significant milestone in CCL’s growth journey as global life sciences player and establishes its presence in Europe.
“We are excited to welcome Dermogyn into the CCL family” expressed Hassan Sheikh – Director and Board Member at CCL. “This acquisition perfectly aligns with our growth strategy and reinforces our commitment to deliver exceptional healthcare solutions to patients globally. Leveraging Dermogyn’s expertise and product offerings, we are confident in further strengthening our consumer health portfolio.“
CCL will work closely with the existing Dermogyn management to ensure a seamless integration and capitalize on synergies. Together, the team will focus on advancing research and development, expanding product availability, and providing comprehensive support to healthcare providers and patients in Europe and around the world.
